Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection

Phase 4

Completed

Conditions: Impotence

Interventions: Drug: tadalafil
Drug: sildenafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 160

Registration Number: NCT00547352

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection

Phase 3

Completed

Conditions: Impotence

Interventions: Drug: placebo
Drug: tadalafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 343

Registration Number: NCT00547495

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Hokkaido, Japan

Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: Atomoxetine

First Posted Date: 2007-10-19

Last Posted Date: 2010-08-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 125

Registration Number: NCT00546910

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolfenbüttel, Germany

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: teriparatide 20 micrograms/day subcutaneous
Drug: salmon calcitonin 100 IU/day subcutaneous

First Posted Date: 2007-10-12

Last Posted Date: 2007-10-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00542984

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

PTH Comparison in Post Menopausal Women

Phase 3

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: teriparatide 20 micrograms/day subcutaneous
Drug: calcitonin 100 IU/day subcutaneous

First Posted Date: 2007-10-12

Last Posted Date: 2007-10-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 63

Registration Number: NCT00543218

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) Mon-Fri from 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tao-Yuan, Taiwan

A Study of the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: teriparatide 20 micrograms/day subcutaneous
Drug: salmon calcitonin 100 IU/day subcutaneous

First Posted Date: 2007-10-12

Last Posted Date: 2007-10-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 104

Registration Number: NCT00543023

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shatin, China

A Study for Patients With Non-Hodgkin's Lymphomas

Phase 2

Completed

Conditions: B-Cell Lymphoma
T-Cell Lymphoma

Interventions: Drug: enzastaurin

First Posted Date: 2007-10-12

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 57

Registration Number: NCT00542919

Locations: 🇵🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lima, Peru

Treatment Compliance in Children and Adolescents on ADHD Medication

Completed

Conditions: ADHD

Interventions: Drug: stimulants (any approved ADHD medication)
Drug: Atomoxetine

First Posted Date: 2007-10-08

Last Posted Date: 2009-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 518

Registration Number: NCT00540826

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Homburg, Germany

Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2007-10-05

Last Posted Date: 2011-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 542

Registration Number: NCT00540241

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Homburg, Germany

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil
Drug: Tamsulosin

First Posted Date: 2007-10-05

Last Posted Date: 2010-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 151

Registration Number: NCT00540124

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy